Market Place
Sourcing Support
Dexcel`s Generics Tafamidis Receives Tentative Approval in US
15 Oct 2024 //
FDA
BridgeBio Shares Data On Serum TTR Increase With Acoramidis
30 Aug 2024 //
GLOBENEWSWIRE
Zenara Pharma`s Generics Tafamidis Receives Tentative Approval in US
21 Aug 2024 //
FDA
Alnylam touts `big-win scenario` for closely watched heart trial
25 Jun 2024 //
FIERCE PHARMA
First ever life-saving treatment for rare heart condition available on the NHS
13 May 2024 //
PRESS RELEASE
Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM
13 May 2024 //
PHARMAPHORUM
Pfizer`s tafamidis will hold its own against new meds: analysts
18 Sep 2023 //
FIERCE PHARMA
Pfizer, Scripps Sue to Block Copy of ‘Most Expensive’ Heart Drug
12 Aug 2023 //
BLOOMBERG LAW
FDA Confirms Paragraph IV Patent Litigation for Tafamidis Capsules
30 Jun 2023 //
FDA
Pfizer prevails in proposed class action lawsuit over copays
06 Apr 2023 //
FIERCE PHARMA
Pfizer’s VYNDAQEL/VYNDAMAX Reduces Risk of All-Cause Mortality by 41% in ATTR-CM
20 Dec 2021 //
BUSINESSWIRE
NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition
13 May 2021 //
PHARMAPHORUM
Pfizer Vyndaqel copay lawsuit could bring drug pricing shockwave
13 Oct 2020 //
FIERCE PHARMA
Tafamidis After Therapy Delay Provides Long-Term Benefit for Patients
09 Oct 2020 //
FIRSTWORLDPHARMA
Regulator OKs Pfizer’s cardiomyopathy drug Vyndamax
23 Aug 2020 //
KOREABIOMEDICALREVIEW
Vyndaqel, Ibrance boost Pfizer as it eyes COVID-19 shot launch
29 Jul 2020 //
FIERCE PHARMA
Vyndaqel® (active substances: tafamidis and tafamidis meglumine)
22 Jun 2020 //
SWISSMEDIC
Vyndaqel first treatment approved in Europe for ATTR-CM
19 Feb 2020 //
PHARMA TIMES
European Commission Approves VYNDAQEL®, the First Treatment in the EU (ATTR-CM)
18 Feb 2020 //
PRESS RELEASE
Pfizer`s Vyndaqel off and running thanks to diagnosis push
29 Jan 2020 //
FIERCE PHARMA
Pfizer`s Vyndaqel off and running thanks to diagnosis push
29 Jan 2020 //
FIERCE PHARMA
Pfizer’s early Vyndaqel launch numbers are off the charts. Should Alnylam be worried?
02 Nov 2019 //
FIERCE PHARMA
Pfizer`s Vyndaqel franchise, buoyed by diagnose, is poised for `a decisive beat`
19 Oct 2019 //
FIERCE PHARMA
AllianceRx Walgreens Prime Issues Updated List of New Specialty Drugs
16 Aug 2019 //
PR NEWSWIRE
Alnylam`s Onpattro back in the game against Ionis, thanks to NICE U-turn
09 Jul 2019 //
FIERCE PHARMA
Pfizer’s tafamidis worth far more than $1.5B: analyst
30 May 2019 //
FIERCE PHARMA
Pfizer`s Vyndaqel, Vyndamax win US nod for rare disease
08 May 2019 //
PHARMA TIMES
Pfizer revs up for blockbuster fight as tafamidis nabs FDA nod
07 May 2019 //
FIERCE PHARMA
Pfizer prospects for tafamidis market
30 Apr 2019 //
BIOPHARMADIVE
The 20 most expensive retail drugs in 2018
29 Dec 2018 //
FIERCE PHARMA
Pfizer drug reduces mortality in patients with fatal heart disease
29 Aug 2018 //
PHARMA PHORUM
Pfizer`s Tafamidis Will Be Standard Of Care For A Not-So-Rare Disease
29 Aug 2018 //
SEEKING ALPHA
Pfizer Achieves Success In Rare Heart Disease Study
28 Aug 2018 //
SEEKING ALPHA
Pfizer`s tafamidis score still leaves `door open` for Alnylam rival: analysts
28 Aug 2018 //
FIERCE PHARMA
Pfizer impresses cardio crowd with tafamidis in ATTR-CM
28 Aug 2018 //
ENDPTS
Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more
27 Aug 2018 //
FIERCE PHARMA
Pfizer eyes ATTR cardiomyopathy filing for tafamidis after acing phase 3 trial
27 Aug 2018 //
FIERCE BIOTECH
Pfizer`s drug for rare heart disease gets a boost
27 Aug 2018 //
BUSINESS TIMES
Pfizer gets breakthrough status from FDA for cardiomyopathy drug
27 May 2018 //
PRESS RELEASE
Pfizer`s tafamidis receives US FDA breakthrough therapy status
24 May 2018 //
PHARMABIZ
Pfizer`s ph 3 ATTR-ACT study of tafamidis to treat transthyretin cardiomyopathy
30 Mar 2018 //
PHARMABIZ
Pfizer`s rare heart disease drug succeeded in a late-stage study
29 Mar 2018 //
CNBC
Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin
06 Jun 2017 //
BUSINESSWIRE
Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO
06 Jun 2017 //
BUSINESSWIRE
